Gentiopicroside

Gentiopicroside at a Glance

Gentiopicroside — historically gentiopicrin — is the principal secoiridoid glycoside of gentian root (Gentiana spp.) and the abundant bitter molecule behind gentian’s centuries-old use as a bitter digestive tonic. Secoiridoids are ring-opened iridoids built biosynthetically from loganin via secologanin; gentiopicroside is the gentian genus’s signature member, a chemical cousin of olive’s oleuropein and of the iridoid harpagide.

Its traditional role is as an amarum (a bitter): taken shortly before meals, gentian’s intense bitterness is held to stimulate saliva, gastric acid and bile flow and so prime the gut for digestion. That human use is of the whole bitter herb — gentian tincture, tea or bitters formula — not of the isolated molecule.

Beyond the bitter tonic, gentiopicroside carries a broad preclinical profile: hepatoprotective, anti-inflammatory, antinociceptive and antidiabetic effects, almost all in cells and animals ^{1,2Reference 1Liu B et al. · 2024ReviewRegulatory mechanisms of gentiopicroside on human diseases: a brief reviewView study →Reference 2Kui L et al. · 2025Therapeutic efficacy and mechanisms of gentiopicroside in various diseasesView study →}. Two honest caveats frame the whole page. First, much of the liver and anti-inflammatory pharmacology was done with gentiopicroside from Gentiana scabra or G. macrophylla rather than the European G. lutea of Western bitters. Second, its oral bioavailability is low (~10% in rats), which tempers claims built on high in-vitro or injected doses ^{6,7Reference 6Chang-Liao WL et al. · 2012AnimalIsolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion ratsView study →Reference 7Wang CH et al. · 2007AnimalPharmacokinetic behavior of gentiopicroside from decoction of Radix Gentianae, Gentiana macrophylla after oral administration in rats: a pharmacokinetic comparison with gentiopicroside after oral and intravenous administration aloneView study →}.

The Gentian Bitter Principle

Gentian is the archetypal bitter tonic, and gentiopicroside is the molecule that makes gentian root abundantly bitter. In the language of traditional Western herbalism it is an amarum — a “pure bitter” whose therapeutic action is held to be its bitterness: tasted before a meal, it is thought to trigger a reflex stimulation of salivary, gastric and biliary secretion that improves appetite and digestion.

There is a real receptor biology beneath the folk mechanism. Bitterness is sensed by the TAS2R family of bitter taste receptors, and these receptors are not confined to the tongue — they are expressed extra-orally in the stomach, gut and elsewhere. Bitter agonists acting on gut TAS2Rs modulate the release of the appetite and gastric-motility hormone ghrelin ^{12Reference 12Janssen S et al. · 2011Bitter taste receptors and α-gustducin regulate the secretion of ghrelin with functional effects on food intake and gastric emptyingView study →}, and bitter compounds can stimulate gastric acid secretion directly through TAS2R signalling in stomach parietal cells ^{13Reference 13Liszt KI et al. · 2017Caffeine induces gastric acid secretion via bitter taste signaling in gastric parietal cellsView study →}. That gives the “bitters stimulate digestion” tradition a plausible molecular route: a bitter secoiridoid engaging bitter receptors along the digestive tract. Notably, gentian’s own bitter receptors have been shown to act in human skin too — a Gentiana lutea bitter extract modulated lipid synthesis in keratinocytes via bitter-taste-receptor signalling in vitro and in a human study, direct evidence that gentian bitters engage functional TAS2Rs in human tissue ^{11Reference 11Wölfle U et al. · 2017In vitroThe herbal bitter drug Gentiana lutea modulates lipid synthesis in human keratinocytes in vitro and in vivoView study →}.

A subtlety worth stating: gentiopicroside is the most abundant bitter of gentian, but not the most potent one. The trace secoiridoid amarogentin is one of the most bitter substances known (bitter at extreme dilution) and dominates the perceived bitterness of the root despite being present in tiny amounts (amarogentin also has its own separately-studied bioactivity, e.g. anti-proliferative effects in a mouse skin-carcinogenesis model) ^{3,10Reference 3Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic reviewView study →Reference 10Saha P et al. · 2006AnimalAmarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis modelView study →}; sweroside and swertiamarin add to the bitter secoiridoid pool ^{3Reference 3Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic reviewView study →}. So gentiopicroside supplies the bulk of the bitter mass, amarogentin the sharpest edge — together they make gentian the reference “bitter.” Whether the isolated molecule reproduces the whole herb’s secretagogue effect at ordinary bitters doses has not been cleanly shown; the digestive-tonic evidence is traditional and whole-herb, and the receptor pharmacology above is the mechanistic scaffolding, not a trial of gentiopicroside.

Hepatoprotective & Anti-Inflammatory Research

The largest slice of modern gentiopicroside research is preclinical liver protection and anti-inflammatory pharmacology — fitting for a molecule whose parent herb (long dan, Gentiana scabra) is a classic Chinese “liver-clearing” bitter. The key honesty note is that this is animal and cell work, mostly on gentiopicroside isolated from G. scabra / G. macrophylla, and human evidence remains at the level of the whole herb.

In rodent liver-injury models, gentiopicroside is hepatoprotective across several insults: it reduced apoptosis and mortality in D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure ^{5Reference 5Lian LH et al. · 2010AnimalAnti-apoptotic activity of gentiopicroside in D-galactosamine/lipopolysaccharide-induced murine fulminant hepatic failureView study →}, protected against liver ischaemia–reperfusion injury ^{6Reference 6Chang-Liao WL et al. · 2012AnimalIsolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion ratsView study →}, and in more recent work improved non-alcoholic steatohepatitis (NASH) and fibrosis by suppressing the TLR4 and NLRP3-inflammasome signalling pathways ^{4Reference 4Yong Q et al. · 2024Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathwaysView study →}. Reviews collate additional antioxidant (Keap1–Nrf2), antidiabetic and neuroprotective activity, while flagging the same limitation — no large randomised human trials ^{1,2Reference 1Liu B et al. · 2024ReviewRegulatory mechanisms of gentiopicroside on human diseases: a brief reviewView study →Reference 2Kui L et al. · 2025Therapeutic efficacy and mechanisms of gentiopicroside in various diseasesView study →}.

The anti-inflammatory mechanism is reasonably well mapped for a natural product. Gentiopicroside suppresses NF-κB activation (inhibiting IKKβ phosphorylation and downstream IκB degradation) and dampens the MAPK cascade (p38/ERK/JNK), lowering COX-2, PGE₂ and pro-inflammatory cytokines (TNF-α, IL-6) ^{2Reference 2Kui L et al. · 2025Therapeutic efficacy and mechanisms of gentiopicroside in various diseasesView study →}. Medicinal-chemistry work has gone further, synthesising gentiopicroside derivatives as selective COX-2 inhibitors — acylated analogues that outperformed the parent in an animal ear-oedema model, an effort explicitly motivated by gentiopicroside’s own high water solubility and modest potency ^{8Reference 8Ren G et al. · 2023Synthesis and biological evaluation of gentiopicroside derivatives as novel cyclooxygenase-2 inhibitors with anti-inflammatory activityView study →}. On the analgesic side, gentiopicroside is antinociceptive in neuropathic-pain and diabetic-neuropathy models, where it ameliorated hyperalgesia and restored nerve function via PPAR-γ/AMPK/ACC signalling ^{9Reference 9Lu Y et al. · 2018Gentiopicroside ameliorates diabetic peripheral neuropathy by modulating PPAR-γ/AMPK/ACC signaling pathwayView study →}.

What It's Used For

Gentiopicroside’s evidence base is preclinical for the isolate and traditional for the herb. The human “use” is the bitter tonic (whole gentian); the isolated-molecule data are animal and cell studies of liver protection, inflammation and pain.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. No row rests on an isolated-gentiopicroside human trial; read the per-row basis.

01HepatoprotectiveShaky44%Multiple rodent liver-injury models (D-GalN/LPS, I/R, NASH/fibrosis) — isolate ^{4,5,6Reference 4Yong Q et al. · 2024Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathwaysView study →Reference 5Lian LH et al. · 2010AnimalAnti-apoptotic activity of gentiopicroside in D-galactosamine/lipopolysaccharide-induced murine fulminant hepatic failureView study →Reference 6Chang-Liao WL et al. · 2012AnimalIsolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion ratsView study →}

02Anti-inflammatory / analgesicShaky40%Isolate: NF-κB/MAPK suppression, lower COX-2; antinociceptive in nerve-pain models ^{2,8,9Reference 2Kui L et al. · 2025Therapeutic efficacy and mechanisms of gentiopicroside in various diseasesView study →Reference 8Ren G et al. · 2023Synthesis and biological evaluation of gentiopicroside derivatives as novel cyclooxygenase-2 inhibitors with anti-inflammatory activityView study →Reference 9Lu Y et al. · 2018Gentiopicroside ameliorates diabetic peripheral neuropathy by modulating PPAR-γ/AMPK/ACC signaling pathwayView study →}

03Digestive bitter tonic (amarum)Shaky34%Traditional whole-herb use + extra-oral TAS2R bitter-receptor mechanism (ghrelin, gastric acid) ^{11,12,13Reference 11Wölfle U et al. · 2017In vitroThe herbal bitter drug Gentiana lutea modulates lipid synthesis in human keratinocytes in vitro and in vivoView study →Reference 12Janssen S et al. · 2011Bitter taste receptors and α-gustducin regulate the secretion of ghrelin with functional effects on food intake and gastric emptyingView study →Reference 13Liszt KI et al. · 2017Caffeine induces gastric acid secretion via bitter taste signaling in gastric parietal cellsView study →}

04Antidiabetic / diabetic neuropathyShaky26%Single-model rodent data (PPAR-γ/AMPK/ACC) + review-level metabolic claims ^{9,2Reference 9Lu Y et al. · 2018Gentiopicroside ameliorates diabetic peripheral neuropathy by modulating PPAR-γ/AMPK/ACC signaling pathwayView study →Reference 2Kui L et al. · 2025Therapeutic efficacy and mechanisms of gentiopicroside in various diseasesView study →}

Mechanisms

The load-bearing point is the split: the TAS2R row is the mechanism of the traditional human use (a bitter, tasted), while the NF-κB/MAPK/TLR4 rows are the mechanism of the preclinical liver/anti-inflammatory pharmacology (the swallowed, absorbed molecule) — two different stories that the page keeps separate.

Pharmacokinetics

Gentiopicroside is a large, polar secoiridoid glycoside, and its defining PK fact is low oral bioavailability. In rats its absolute oral bioavailability was about 10%, with a peak plasma concentration reached quickly (Cmax ~5.8 µg/mL within ~45 min) and a short elimination half-life (~3.3 h) after an oral dose ^{6Reference 6Chang-Liao WL et al. · 2012AnimalIsolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion ratsView study →}. Its clearance is comparatively fast — intravenous half-life on the order of an hour — and cytochrome P450 is involved in its metabolism: co-dosing a CYP inhibitor raised its plasma exposure and residence time ^{7Reference 7Wang CH et al. · 2007AnimalPharmacokinetic behavior of gentiopicroside from decoction of Radix Gentianae, Gentiana macrophylla after oral administration in rats: a pharmacokinetic comparison with gentiopicroside after oral and intravenous administration aloneView study →}. Formulation matters: gentiopicroside is absorbed better from a whole gentian decoction than as the purified compound (roughly 1.8–2.5× higher relative bioavailability from decoctions in rats), a matrix effect that mirrors the herb-versus-isolate theme of the whole page ^{7Reference 7Wang CH et al. · 2007AnimalPharmacokinetic behavior of gentiopicroside from decoction of Radix Gentianae, Gentiana macrophylla after oral administration in rats: a pharmacokinetic comparison with gentiopicroside after oral and intravenous administration aloneView study →}. Reviews put the practical oral bioavailability at only ~12–18%, and the molecule’s high water solubility and rapid clearance are exactly why medicinal chemists have pursued more lipophilic derivatives ^{2,8Reference 2Kui L et al. · 2025Therapeutic efficacy and mechanisms of gentiopicroside in various diseasesView study →Reference 8Ren G et al. · 2023Synthesis and biological evaluation of gentiopicroside derivatives as novel cyclooxygenase-2 inhibitors with anti-inflammatory activityView study →}. There is no human pharmacokinetic dataset for the isolate.

Clinical Trials

There are no controlled clinical trials of isolated gentiopicroside. Its human footprint is entirely the whole bitter herb — gentian root as a traditional appetite/digestive bitter and as a component of multi-herb bitters and long dan formulas ^{3Reference 3Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic reviewView study →}. All the hepatoprotective, anti-inflammatory, analgesic and antidiabetic findings are preclinical.

Last checked: July 2026.

Isolate vs. Plant Studies

Gentiopicroside is a clean example of the isolate-vs-plant divergence. The human use is the plant: gentian root, as a bitter tincture, tea or bitters formula taken before meals — a whole-herb, traditional practice where the perceived bitterness (and much of the secretagogue effect) is carried by the whole secoiridoid pool, with the trace amarogentin dominating potency and gentiopicroside supplying the bulk ^{3Reference 3Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic reviewView study →}. The isolated-molecule evidence, by contrast, is preclinical: the D-GalN/LPS, ischaemia–reperfusion and NASH liver models ^{4,5,6Reference 4Yong Q et al. · 2024Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathwaysView study →Reference 5Lian LH et al. · 2010AnimalAnti-apoptotic activity of gentiopicroside in D-galactosamine/lipopolysaccharide-induced murine fulminant hepatic failureView study →Reference 6Chang-Liao WL et al. · 2012AnimalIsolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion ratsView study →}, the NF-κB/MAPK anti-inflammatory mechanism ^{2Reference 2Kui L et al. · 2025Therapeutic efficacy and mechanisms of gentiopicroside in various diseasesView study →}, and the diabetic-neuropathy model ^{9Reference 9Lu Y et al. · 2018Gentiopicroside ameliorates diabetic peripheral neuropathy by modulating PPAR-γ/AMPK/ACC signaling pathwayView study →} all used purified gentiopicroside in cells or rodents. Two transferability caveats compound this. First, species: a large share of the liver/anti-inflammatory pharmacology used gentiopicroside from Gentiana scabra or G. macrophylla, not the European G. lutea that anchors Western gentian bitters ^{1Reference 1Liu B et al. · 2024ReviewRegulatory mechanisms of gentiopicroside on human diseases: a brief reviewView study →}. Second, delivery: the isolate is absorbed poorly and less efficiently than the same molecule in a gentian decoction ^{7Reference 7Wang CH et al. · 2007AnimalPharmacokinetic behavior of gentiopicroside from decoction of Radix Gentianae, Gentiana macrophylla after oral administration in rats: a pharmacokinetic comparison with gentiopicroside after oral and intravenous administration aloneView study →}. The correct framing is therefore: traditional human use of the herb + a broad preclinical profile for the isolate, with the two connected but not interchangeable.

Its Role in Plants

Gentiopicroside is a secoiridoid — a ring-opened iridoid. Its biosynthesis runs through the terpenoid–iridoid pathway: geraniol-derived precursors are elaborated to loganin, oxidative cleavage of loganin gives secologanin, and further secoiridoid metabolism yields gentiopicroside and its relatives (sweroside, swertiamarin, amarogentin) in the Gentianaceae. This is the same biosynthetic branch that produces olive’s oleuropein, and — via secologanin — feeds the monoterpene indole alkaloids; loganin is the shared precursor.

Functionally, gentiopicroside is a defence and deterrence compound. Its intense bitterness deters herbivores and, like many secoiridoids, it can release reactive aglycones on enzymatic hydrolysis after tissue damage — chemistry that discourages feeding and inhibits microbes. Consistent with a protective role, it concentrates in the perennial root/rhizome (the pharmacopoeial part) far more than in leaves or flowers ^{3Reference 3Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic reviewView study →}.

Prevalence in Nature

Gentiopicroside is the dominant secoiridoid of the genus Gentiana and a marker of the family Gentianaceae. It is richest in the root and rhizome, and reported up to about 13% of an ethanol extract of Gentianae Radix (Chinese gentian root) — a striking level for a single glycoside, though the figure is an extract percentage and clean whole-root % dry-weight numbers are rarely published ^{6Reference 6Chang-Liao WL et al. · 2012AnimalIsolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion ratsView study →}. Content varies strongly with species, provenance, plant part (root > leaf > flower) and processing; leaves and flowers carry secoiridoids too and have been proposed as alternative bitter sources, but differ chemically from the root ^{3Reference 3Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic reviewView study →}.

Beyond the medicinal gentians it occurs across other Gentianaceae — common centaury (Centaurium erythraea), large-leaf gentian / qin jiao (Gentiana macrophylla), and Swertia species — alongside the co-occurring secoiridoids amarogentin, sweroside and swertiamarin and the genus’s characteristic xanthones (mangiferin, isogentisin) ^{1,3Reference 1Liu B et al. · 2024ReviewRegulatory mechanisms of gentiopicroside on human diseases: a brief reviewView study →Reference 3Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic reviewView study →}.

Major Natural Sources

Source	Plant part	Reported gentiopicroside content
Gentian (Gentiana lutea)	root / rhizome	Dominant secoiridoid; % dry-wt rarely quantified cleanly
Chinese gentian / long dan (Gentiana scabra)	root / rhizome	Up to ~13% of an ethanol extract of Gentianae Radix 6Reference 6Chang-Liao WL et al. · 2012AnimalIsolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion ratsView study →
Large-leaf gentian / qin jiao (Gentiana macrophylla)	root	Major secoiridoid (source in much PK work) 7Reference 7Wang CH et al. · 2007AnimalPharmacokinetic behavior of gentiopicroside from decoction of Radix Gentianae, Gentiana macrophylla after oral administration in rats: a pharmacokinetic comparison with gentiopicroside after oral and intravenous administration aloneView study →
Common centaury (Centaurium erythraea)	aerial parts / whole herb	Present as a characteristic bitter secoiridoid

Figures vary widely with species, plant part, season and processing; the root is consistently the richest part ^{3,6Reference 3Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic reviewView study →Reference 6Chang-Liao WL et al. · 2012AnimalIsolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion ratsView study →}.

Discovery & Synthesis

Gentiopicroside was first obtained from gentian (Gentiana lutea) root in the nineteenth century and named gentiopicrin — from Gentiana plus the Greek pikros, “bitter” — as the crystalline bitter principle of the root, part of the era’s broad effort to isolate the “bitters” of medicinal plants. (This is pre-PubMed primary chemistry, consistently reported across the modern reviews but not verifiable here to an original digitised source.) Its secoiridoid structure and its place in the iridoid/secologanin biosynthetic scheme were established through twentieth-century natural-product chemistry ^{1,3Reference 1Liu B et al. · 2024ReviewRegulatory mechanisms of gentiopicroside on human diseases: a brief reviewView study →Reference 3Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic reviewView study →}.

Manufacture today is by extraction, not synthesis. Gentiopicroside is obtained from gentian root (a well-supplied raw material used for bitters, aperitifs and traditional medicine) by aqueous/hydroalcoholic extraction; there is no commercial total synthesis. The interesting synthetic chemistry has instead been semi-synthetic derivatisation — acylating gentiopicroside to more lipophilic COX-2-inhibiting analogues to work around its high water solubility and low bioavailability ^{8Reference 8Ren G et al. · 2023Synthesis and biological evaluation of gentiopicroside derivatives as novel cyclooxygenase-2 inhibitors with anti-inflammatory activityView study →}.

Patents: not yet researched.

Toxicity & Safety

Gentiopicroside carries a low toxicity flag. It is the principal bitter of gentian root — a plant with a long history of use as a food/beverage bitter (aperitifs, digestive bitters) and traditional medicine — and no distinctive organ toxicity is reported for the compound at relevant intakes; the preclinical liver studies show it as protective, not hepatotoxic ^{1,4,5Reference 1Liu B et al. · 2024ReviewRegulatory mechanisms of gentiopicroside on human diseases: a brief reviewView study →Reference 4Yong Q et al. · 2024Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathwaysView study →Reference 5Lian LH et al. · 2010AnimalAnti-apoptotic activity of gentiopicroside in D-galactosamine/lipopolysaccharide-induced murine fulminant hepatic failureView study →}. The practical cautions are pharmacological and traditional rather than toxicological.

Safety at a Glance

✅ Low / no toxicity

• Low-toxicity food/beverage bitter. The bitter principle of gentian root, long used in aperitifs and digestive bitters; preclinical liver data show protection, not injury ^{1,4,5Reference 1Liu B et al. · 2024ReviewRegulatory mechanisms of gentiopicroside on human diseases: a brief reviewView study →Reference 4Yong Q et al. · 2024Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathwaysView study →Reference 5Lian LH et al. · 2010AnimalAnti-apoptotic activity of gentiopicroside in D-galactosamine/lipopolysaccharide-induced murine fulminant hepatic failureView study →}.
• It is a bitter secretagogue. As a stimulant of gastric acid and digestive secretion, concentrated gentian bitters are traditionally cautioned in active peptic ulcer, gastritis or reflux, where extra acid stimulation is unwanted ^{12,13Reference 12Janssen S et al. · 2011Bitter taste receptors and α-gustducin regulate the secretion of ghrelin with functional effects on food intake and gastric emptyingView study →Reference 13Liszt KI et al. · 2017Caffeine induces gastric acid secretion via bitter taste signaling in gastric parietal cellsView study →}.
• Isolate ≠ herb, and species matters. Human use and safety experience is of whole gentian; much isolate pharmacology used G. scabra/G. macrophylla, not European G. lutea, so don’t read isolate studies as herb-safety data ^{1Reference 1Liu B et al. · 2024ReviewRegulatory mechanisms of gentiopicroside on human diseases: a brief reviewView study →}.
• Poor oral bioavailability. ~10% in rats — high in-vitro/injected doses overstate what an oral dose delivers ^{6,7Reference 6Chang-Liao WL et al. · 2012AnimalIsolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion ratsView study →Reference 7Wang CH et al. · 2007AnimalPharmacokinetic behavior of gentiopicroside from decoction of Radix Gentianae, Gentiana macrophylla after oral administration in rats: a pharmacokinetic comparison with gentiopicroside after oral and intravenous administration aloneView study →}.

Reproductive and developmental data for isolated gentiopicroside are not characterised, and traditional sources have historically cautioned strong bitters in pregnancy on general grounds; pregnancy and lactation are per-herb/per-supplement decisions made on the gentian monograph where intake is decided, not adjudicated on this molecule page. No isolate genotoxicity or repeat-dose package is established here.

Dosage

There is no established dose for isolated gentiopicroside. Human use is the whole bitter herb: gentian root tincture, tea or a bitters formula, taken shortly before meals as an appetite/digestive stimulant and dosed in drops of tincture, not milligrams of the isolate — the bitterness itself is the “dose” ^{3Reference 3Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic reviewView study →}.

Because gentiopicroside is poorly absorbed (~10% oral bioavailability in rats) and is better absorbed from a whole gentian decoction than as the purified compound, animal isolate doses do not translate into a human milligram figure ^{6,7Reference 6Chang-Liao WL et al. · 2012AnimalIsolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion ratsView study →Reference 7Wang CH et al. · 2007AnimalPharmacokinetic behavior of gentiopicroside from decoction of Radix Gentianae, Gentiana macrophylla after oral administration in rats: a pharmacokinetic comparison with gentiopicroside after oral and intravenous administration aloneView study →}. These are traditional whole-herb practices and preclinical research figures, not a personal recommendation.

References

1. Liu B, et al. (2024). Regulatory mechanisms of gentiopicroside on human diseases: a brief review. Naunyn-Schmiedeberg’s Archives of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/37632552/
2. Kui L, et al. (2025). Therapeutic efficacy and mechanisms of gentiopicroside in various diseases. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/41378205/
3. Ponticelli M, et al. (2023). The healing bitterness of Gentiana lutea L., phytochemistry and biological activities: A systematic review. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/36423749/
4. Yong Q, et al. (2024). Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/38917754/
5. Lian LH, et al. (2010). Anti-apoptotic activity of gentiopicroside in D-galactosamine/lipopolysaccharide-induced murine fulminant hepatic failure. Chemico-Biological Interactions. https://pubmed.ncbi.nlm.nih.gov/20558151/
6. Chang-Liao WL, et al. (2012). Isolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion rats. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/21855624/
7. Wang CH, et al. (2007). Pharmacokinetic behavior of gentiopicroside from decoction of Radix Gentianae, Gentiana macrophylla after oral administration in rats: a pharmacokinetic comparison with gentiopicroside after oral and intravenous administration alone. Archives of Pharmacal Research. https://pubmed.ncbi.nlm.nih.gov/17958334/
8. Ren G, et al. (2023). Synthesis and biological evaluation of gentiopicroside derivatives as novel cyclooxygenase-2 inhibitors with anti-inflammatory activity. Drug Design, Development and Therapy. https://pubmed.ncbi.nlm.nih.gov/36992901/
9. Lu Y, et al. (2018). Gentiopicroside ameliorates diabetic peripheral neuropathy by modulating PPAR-γ/AMPK/ACC signaling pathway. Cellular Physiology and Biochemistry. https://pubmed.ncbi.nlm.nih.gov/30308492/
10. Saha P, et al. (2006). Amarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis model. Cancer Letters. https://pubmed.ncbi.nlm.nih.gov/16517061/
11. Wölfle U, et al. (2017). The herbal bitter drug Gentiana lutea modulates lipid synthesis in human keratinocytes in vitro and in vivo. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/28829355/
12. Janssen S, et al. (2011). Bitter taste receptors and α-gustducin regulate the secretion of ghrelin with functional effects on food intake and gastric emptying. Proceedings of the National Academy of Sciences USA. https://pubmed.ncbi.nlm.nih.gov/21245306/
13. Liszt KI, et al. (2017). Caffeine induces gastric acid secretion via bitter taste signaling in gastric parietal cells. Proceedings of the National Academy of Sciences USA. https://pubmed.ncbi.nlm.nih.gov/28696284/

View all 13 references▾